OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Biotechnology is 110. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Single-cell RNA-seq keeps cells alive	4570
Synthetic biologics provide a path to target bHLH transcription factors	2222
AI’s plastic recycling	1220
Denmark invests in mucosal vaccines	1039
Wireless microelectronic fibers to discover gut and brain pathways	968
Overcoming unpredictability in biotech patents by tailored claiming aligned with genuine enablement	785
Framework for predicting alloreactivity in hematopoietic cell transplants	732
Bite-sized solutions	539
An optimized toolkit for prime editing	537
Orchestration of secondary metabolite production in Streptomyces species	479
Author Correction: Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion	477
Human periportal liver assembloids	444
People	403
Cancer Moonshot aims at liquid biopsies	391
A competitive precision CRISPR method to identify the fitness effects of transcription factor binding sites	386
Cellular shuttles put mislocalized proteins in their right place	384
Diffusion model expands RoseTTAFold’s power	383
Reflective multi-immersion microscope objectives inspired by the Schmidt telescope	362
Droplet-based transcriptome profiling of individual synapses	344
Author Correction: LAMP-Seq enables sensitive, multiplexed COVID-19 diagnostics using molecular barcoding	338
Author Correction: Simultaneous editing of three homoeoalleles in hexaploid bread wheat confers heritable resistance to powdery mildew	313
Fresh from the biotech pipeline: FDA turmoil overshadows 2025 approvals	309
Chem-map profiles drug binding to chromatin in cells	294
Engineered serum markers for non-invasive monitoring of gene expression in the brain	269
Fluorescence microscopy resolution increases to near-atomic level	261

Integrating medicine, engineering and business to educate early-stage researchers in cardiovascular device development	259
TRGT-ing the dark genome to accurately characterize tandem repeats at scale	254
Engineering innate immune cells for cancer immunotherapy	253
Biopharma dives into tumor-seeking radioactive drugs	240
Behind the graduate mental health crisis in science	238
Generative models for protein structures and sequences	238
Synthetic biology’s uncertain regulatory future in the wake of Loper Bright Enterprises v. Raimondo	237
Design of optimized epigenetic regulators for durable gene silencing with application to PCSK9 in nonhuman primates	234
Democratizing knowledge representation with BioCypher	234
Establishing a commercial solution for extremely rare genetic diseases	230
The lysosomal degraders	227
Programming biology: next-gen AI firms raise billions to design better medicines	225
Enhancing prime editing in hematopoietic stem and progenitor cells by modulating nucleotide metabolism	224
Programmable promoter editing for precise control of transgene expression	221
High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition	221
The world’s first CRISPR therapy is approved: who will receive it?	214
Automated reconstruction of whole-embryo cell lineages by learning from sparse annotations	213
Variant to function mapping at single-cell resolution through network propagation	208
Dual SORT LNPs for multi-organ base editing	202
Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome	202
Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy	201
Agentic AI and the rise of in silico team science in biomedical research	196
In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice	195
An oncolytic virus–T cell chimera for cancer immunotherapy	194
Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids	194
Fungal architecture is a thing, and it’s eye-catching	194
Predicting transcriptional outcomes of novel multigene perturbations with GEARS	192
Single-cell nanobody-based profiles of multiple epigenetic modalities and chromatin velocity	192
Biotech news from around the world	191
AI predicts cancer relapse from slides	191
3Q22 — more malaise in the markets	190
Biotech news from around the world	189
The need for need-finding in medical education	189
HSV-1’s contribution as a vector for gene therapy	188
People	188
Decoding gene regulation with CRISPR perturbations	183
Precise DNA cleavage using CRISPR-SpRYgests	183
Delix Therapeutics : psychedelics without the trip	178
Towards the non-invasive imaging of brain networks and functions at high resolution	176
Considerations for the future of in vitro gametogenesis in fertility care	167
Gains in early-onset dementia with progranulin open new paths for drug discovery	164
Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression	163
Grand challenges in bioinformatics education and training	162
Orna Therapeutics: circular logic	160
Computationally designed enzymes show potent catalytic activity	160
Sequence Display enables large-scale sequence–activity datasets for rapid protein evolution	160
Adrestia Therapeutics — Gene networks to the rescue	156
FDA approves first MASH drug	155
Artificial miRNA slows Huntington’s	154
Mesenchymal thymic niche cells enable regeneration of the adult thymus and T cell immunity	150

Improving metagenome binning by integrating intrinsic features and taxonomy	149
Connecting research and clinical practice: training the next generation of translational scientists	148
Live cell imaging of signaling networks using a conventional microscope	146
Mapping the patent landscape of cancer diagnostics	144
Prediction of peptide mass spectral libraries with machine learning	143
GLP-1s surprise failure in Alzheimer’s	142
Building synthetic chromosomes one yeast at a time: insights from Sc2.0	141
Next-generation psychedelics: should new agents skip the trip?	140
In vivo base editing reverses a neurodevelopmental disorder	136
Lessons from biotech’s unscientific evolution	135
Delivering 3 billion doses of Comirnaty in 2021	130
David Baltimore (1938–2025)	129
Author Correction: The cost of drug patent expiration date errors	127
A language model beats alphafold2 on orphans	126
Hallucinating functional protein sequences	126
Escaping analysis paralysis in medical training: from FRAZZLE to CALM	124
Retraction Note: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN	122
The promises and challenges of neoantigen cancer vaccines	121
Spatiotemporal multiplexed immunofluorescence imaging of living cells and tissues with bioorthogonal cycling of fluorescent probes	121
Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice	120
Slaughter-free meat hits the grocery shelf	119
A strategy to load, rethread and read protein sequences through a nanopore	118
Detection of mosaic and population-level structural variants with Sniffles2	118
Drug pipeline 4Q22 — sticking around	117
2022 – toughing out the trough	117
Biotech news from around the world	117
Forum: Boyden and Danzl	116
Lab-made antibody stops malaria	114
Genome-edited farm animals from haploid stem cells	113
The devolution of biosimilars regulations	112
Microbiome-friendly phages join the campaign for better antimicrobials	111
Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable	111
Engineering pattern recognition receptors facilitates plant resistance breeding	110
Growth of biotech clusters over several decades through pioneering, variety and entrepreneurial science	110
Consternation follows Marks’ FDA departure	110